Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: Implications for the therapeutic development of RNAi
By J. McBride, Ryan L. Boudreau, S. Harper, Patrick D. Staber, A. M. Monteys, Inâs Martins, Brian L. Gilmore, H. Burstein, R. Peluso, B. Polisky and 2 more. Proceedings of the National Academy of Sciences of the United States of America, 2008
623 citations recorded by the source corpus.
Subfields: Molecular Biology
View Paper: https://www.semanticscholar.org/paper/6441cd996c0e2e883da15ca227b8e673874a9a70
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
- P. McCray
- Joshua T. Mendell
- P. Vivekanandan
- M. Valenza
- E. Cattaneo
- Hun-Way Hwang
- Erik A. Wentzel
- C. Zuccato
Citations in the corpus
- Sustained therapeutic reversal of Huntington’s disease by transient repression of huntingtin synthesis (2012, neutral): “…needs to be delivered by direct intraparenchymal injections, and therapeutic correction is limited to only a small portion of the striatum immediately adjacent to the sites of injection (Boudreau et al., 2009; DiFiglia et al., 2007; Drouet et al., 2009; Harper et al., 2005; McBride et al., 2008).”
- Therapeutic delivery of miR-26a inhibits cancer cell proliferation and induces tumor-specific apoptosis (2009, positive): “Supporting this notion, shRNA-associated toxicity can be mitigated by placing a shRNA into an miRNA-like context (McBride et al., 2008).”
- Current prospects for RNA interference-based therapies (2011, background): “Reduced shRNA export could cause nuclear accumulation and toxicity 63, 64 .”
- Molecular mechanisms and potential therapeutical targets in Huntington's disease. (2010, background): “Beverly Davidson’s group (378) has recently shown that the toxicity of shRNAs could be alleviated by moving the inhibitory RNA sequences into an artificial miRNA scaffold, highlighting the fact that miRNA-based approaches might be more suitable for achieving RNA interference-mediated silencing of mu”
- A construct with fluorescent indicators for conditional expression of miRNA (2008, neutral): “By comparison, pol II promoters drive miRNA expression at lower levels and may be advantageous [4,21].”